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The Wnt/b-catenin signaling pathway plays a major
role in tissue homeostasis, and its dysregulation
can lead to various human diseases. Aberrant activa-
tion of b-catenin is oncogenic and is a critical driver
in the development and progression of human
cancers. Despite the significant potential of targeting
the oncogenic b-catenin pathway for cancer therapy,
the development of specific inhibitors remains insuf-
ficient. Using a T cell factor (TCF)-dependent lucif-
erase-reporter system, we screened for small-mole-
cule compounds that act against Wnt/b-catenin
signaling and identified MSAB (methyl 3-{[(4-methyl-
phenyl)sulfonyl]amino}benzoate) as a selective in-
hibitor of Wnt/b-catenin signaling. MSAB shows
potent anti-tumor effects selectively on Wnt-depen-
dent cancer cells in vitro and in mouse cancer
models. MSAB binds to b-catenin, promoting its
degradation, and specifically downregulates Wnt/
b-catenin target genes. Our findings might represent
an effective therapeutic strategy for cancers ad-
dicted to the Wnt/b-catenin signaling pathway.
INTRODUCTION
The Wnt signaling pathway plays crucial roles in multiple stages
of development and tissue homeostasis (Clevers et al., 2014;
Clevers and Nusse, 2012; Klaus and Birchmeier, 2008). In the
absence of Wnt ligands, the level of cytoplasmic b-catenin is
constantly in check through the action of the destruction com-
plex, which consists of the scaffold protein Axin, adenomatous
polyposis coli (APC), glycogen synthase kinase 3b (GSK3b),
and casein kinase 1 (CK1) (Behrens et al., 1998; MacDonald
et al., 2009). Sequential phosphorylation by CK1 and GSK3b
marks b-catenin for recognition by b-TrCP, an E3 ligase subunit,28 Cell Reports 16, 28–36, June 28, 2016 ª 2016 The Authors.
This is an open access article under the CC BY-NC-ND license (http://which subsequently causes ubiquitination and proteasomal
degradation of b-catenin (Orford et al., 1997; Yost et al., 1996).
When present, Wnt ligands interact with the receptor complex
Frizzled/LRP5/LRP6 (low-density lipoprotein receptor-related
protein), which then triggers a series of downstream events lead-
ing to stabilization and nuclear translocation of b-catenin (Bha-
not et al., 1996; He et al., 2004; Huang and He, 2008). Once in
the nucleus, b-catenin associates with members of T cell factor
(TCF) family of transcription factors (Behrens et al., 1996; Mole-
naar et al., 1996) as well as with transcriptional co-activators
such as CREB-binding protein (CBP), p300, Pygopus (PYGO),
and B cell lymphoma 9 (BCL-9), and it regulates the transcription
of a broad spectrum of downstream target genes involved in
proliferation, fate specification, and differentiation (Hecht et al.,
2000; Kramps et al., 2002; Mosimann et al., 2009; Takemaru
and Moon, 2000).
Since the first discovery of proto-oncogene Int1, now known
asWnt1, misregulation of Wnt signaling has been closely linked
to carcinogenesis (Nusse and Varmus, 1982). Mutations in the
pathway components, including APC, Axin, and b-catenin,
have been found to be closely associated with various types of
cancers (Korinek et al., 1997; Morin et al., 1997; Rubinfeld
et al., 1997; Satoh et al., 2000). During the past decade, exten-
sive efforts have focused on discovering small-molecule inhibi-
tors capable of downregulating such aberrant activation in
cancer cells (Anastas and Moon, 2013; Fang et al., 2016; Hao
et al., 2013; Kahn, 2014; Polakis, 2012). Compounds such as
PKF115-584 and CGP049090 disrupt the interaction between
b-catenin and TCF (Lepourcelet et al., 2004), ICG-001 interrupts
binding between b-catenin and CBP (Emami et al., 2004), and
carnosic acid interferes with b-catenin and BCL9 binding (de la
Roche et al., 2012). Additionally, compounds that target more
upstream of the pathway have been discovered. The Tankyrase
inhibitors IWR-1 (Chen et al., 2009) and XAV939 (Huang et al.,
2009), which stabilize Axin, and the CK1 activator Pyrvinium
(Thorne et al., 2010) enhance the activity of the destruction com-
plex, leading to degradation of b-catenin. However, because
these binding partners or upstream regulators of b-catenincreativecommons.org/licenses/by-nc-nd/4.0/).
have multiple roles, it is conceptually attractive to directly target
b-catenin as opposed to other factors in the Wnt signaling axis.
In this study, we report the discovery of a small molecule,
methyl 3-{[(4-methyl phenyl) sulfonyl] amino} benzoate (MSAB),
that selectively exerts anti-proliferative effects on Wnt-depen-
dent cancer cells. MSAB stimulates the degradation of b-cate-
nin, thus lowering high levels of active b-catenin and suppressing
its nuclear translocation. Furthermore, we present evidence sug-
gesting that it binds to b-catenin.We anticipate that these results
will contribute to the rigorous search for tools capable of selec-
tively suppressing oncogenic Wnt signaling and to the under-
standing of b-catenin biology.
RESULTS
Identification of MSAB as a Small-Molecule Inhibitor of
the Wnt/b-Catenin Signaling Pathway
To identify inhibitor compounds capable of modulating b-cate-
nin-mediated Wnt signaling in cancer, we performed a cell-
based screen in which luciferase is expressed in response to
the signaling activity of Wnt. High-throughput screening was
conducted utilizing HCT116 cells, which carry a mutant allele
of b-catenin that lacks Ser45, the phosphorylation target of
CK1a, resulting in aberrantly high levels of active b-catenin. Us-
ing small-molecule libraries, 22,000 compounds were screened
against HCT116 cells stably transfected with TOP-Luc, a lucif-
erase-based reporter containing TCF binding sites (Korinek
et al., 1997) (Figure S1A). From the initial screen, we identified
56 potential Wnt pathway inhibitors that reduced the TOP-Luc
activity to a level <50% of the level observed in a DMSO-treated
control (Figures S1A and S1B). These small molecules were vali-
dated by assessing the dose-dependent inhibitory effects on
TOP-Luc activity and by measuring compound-responsive
levels of Wnt target gene expression. To control for false posi-
tives, we tested for inhibitory effects on constitutively expressed
luciferase reporter (CMV-Luc) activity as well. Based on these
criteria, 14 compounds advanced (Figure S1C) and were then
tested for Wnt/b-catenin specificity by evaluating growth inhibi-
tory effects onWnt-dependent or independent cancer cells (Akiri
et al., 2009; Vijayakumar et al., 2011) (Figure S1A). A673 and
H460 cells had been reported to carry very low levels of un-
complexed b-catenin and exhibit low TCF-reporter activity.
Additionally, expression of dnTCF4 had shown little effect on
colony formation efficiency in these cell lines (Akiri et al., 2009;
Vijayakumar et al., 2011). Thus, these twowere tested asWnt-in-
dependent cells in this study.
Based on these results, WI-21, hereafter referred to as MSAB,
was selected among the candidates as the strongest and most
selective inhibitor of Wnt/b-catenin signaling activity (Figure 1A
and S1). MSAB treatment of HCT116 human colon cancer cells
resulted in strong inhibition of the TOP-Luc activity in a dose-
dependentmanner while displaying little effect on the expression
of luciferase when driven by CMV-Luc, confirming its specificity
(Figure 1B). In addition, MSAB showed little effect on FOP-Luc
(a scrambled mutant of TCF-promoter element), NF-kB-Luc,
iNOS-Luc, or Notch-Luc reporter activities in the HCT116 cell
line, further demonstrating high selectivity of MSAB against the
Wnt/b-catenin pathway (Figure 1C).In order to test if MSAB could inhibit Wnt signaling activity
stimulated by Wnt3a, HEK293T cells were treated with Wnt3a-
CM (conditioned medium) or Wnt3a recombinant protein, and
the effect of MSAB on the activity of Wnt/b-catenin pathway
was measured by TOP-Luc assay or through western blot anal-
ysis probing for active b-catenin (ABC). Both assays revealed
a dramatic inhibitory effect of MSAB on Wnt3a-mediated Wnt
pathway activation (Figure 1D).
Next, the effects of MSAB on Wnt-mediated cell proliferation
in Wnt-dependent or Wnt-independent cells were examined.
As a result, MSAB inhibited proliferation of Wnt-dependent can-
cer cell lines, but it had little effect on the viability of normal or
immortalized breast epithelial cells (including MCF10A, 184B5,
and 76N), human dermal fibroblasts (HDF), and Wnt-indepen-
dent cancer cell lines (including A673 and H460) at concentra-
tions as high as 10 mM (Figure 1E). By testing TCF-luciferase
activity in these cell lines, we confirmed that Wnt-dependent
cells demonstrate higher Wnt signaling activity than Wnt-inde-
pendent cells (Figure S1D) and that MSAB can selectively inhibit
this activity in Wnt-dependent cells while showing little effect
in Wnt-independent cells and normal human cells (Figure 1F).
Collectively, these results strongly suggest that MSAB is a
potent and selective inhibitor of Wnt-dependent cancer cells.
MSAB Inhibits Growth of Wnt-Dependent Xenograft
Tumors
We next tested whether MSAB shows anti-tumor effects in
human cancer cell-driven xenograft tumors in nude mice. After
the tumors reached a volume of 40 mm3, the mice were injected
intraperitoneally daily with 10 or 20 mg/kg MSAB or with the
vehicle solution (DMSO) for up to 2 weeks. MSAB markedly
reduced the size and weight of various types of Wnt-dependent
HCT116, HT115, and H23 tumors in xenografted mouse models
(Figures 2A–2C). In order to test whether tumor reduction by
MSAB is mediated by apoptosis of tumor cells, we carried out
TUNEL staining and detected a significant increase in TUNEL-
positive apoptotic cells in HCT116 tumor xenografts treated
with MSAB (Figure S2A). Moreover, western blot analysis
showed an increase in the level of cleaved caspase-3 in
HCT116 and H23 xenograft tumor tissues from mice treated
withMSAB (Figure S2B), demonstrating thatMSAB treatment re-
sulted in apoptotic cell death of tumor xenograft cells, leading to
a subsequent reduction in tumor size. Notably, there were no
detectable signs of systemic toxicity, implying minimal off-target
or nonspecific effects of MSAB in vivo. Moreover, MSAB did
not affect the growth of tumors driven by Wnt-independent
H460 cancer cells in the xenograft model (Figure 2D). We
also examined whether MSAB has an inhibitory effect on Wnt-
initiated spontaneously developing mammary tumors (MMTV-
Wnt1 mice). The average tumor growth rates in the treated and
untreated groups were significantly different (Figure 2E). We
also tested several pharmacological metrics. MSAB showed a
moderate bioavailability level at 30.5% absorption. To assess
pharmacokinetics, BALB/c mice were treated with a single intra-
venous or oral dose of MSAB, which resulted in a moderate tis-
sue distribution with a calculated volume distribution of 1.1 l/kg
and moderate clearance of 41 ml/min/kg (Table S1). These re-
sults demonstrate that in addition to in vitro activity observedCell Reports 16, 28–36, June 28, 2016 29
Figure 1. MSAB Is a Small-Molecule Inhibitor of the Wnt/b-Catenin Signaling Pathway
(A) Chemical structure of methyl 3-{[(4-methylphenyl)sulfonyl]amino}benzoate (MSAB).
(B) MSAB inhibits TCF luciferase reporter activity in HCT116 cells. HCT116 cells with luciferase-based reporter containing TCF binding sites (TOP-Luc) or a
constitutively expressed luciferase (CMV-Luc) reporter were treated with MSAB as indicated.
(C) The inhibitory effect of MSAB is specific to TOP-Luc reporter activity and shows little effect on FOP-Luc, iNOS-Luc, NF-kB-Luc, or NOTCH-Luc reporter
activity in transiently transfected HCT116 cells. Renilla-luciferase was used as a control.
(D)Wnt3a-induced TOP-Luc activation and an increase in active b-catenin levels are suppressed byMSAB treatment. HEK293T cells transiently expressing TOP-
Luc reporter were treated with control-conditioned medium (control-CM), Wnt3a-conditioned medium (Wnt3a-CM), or recombinant Wnt3a in the presence of
DMSO or MSAB, followed by a luciferase assay or western blot analysis.
(E) MSAB selectively decreases cell viability ofWnt-dependent cells while showing little effect onWnt-independent cells and normal human cells. MSAB exhibited
cytotoxicity preferentially in Wnt-dependent cancer cells, but not in human normal breast epithelial cells (76N), human normal skin fibroblasts (HDF), or in
immortalized breast epithelial cell lines (184B5 and MCF10A). Cell viability was measured by an SRB (sulforhodamine B) assay.
(F) MSAB selectively inhibited TCF luciferase reporter activity in Wnt-dependent cells while showing little effect in Wnt-independent cells.
See also Figure S1.
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Figure 2. MSAB Inhibits Tumor Growth of Wnt-Dependent Cancer Cells in a Mouse Xenograft Model
(A–D) Inamousexenograftmodel,MSAB inhibited tumorgrowthof theWnt-dependentcancercell lines (A)HCT116, (B)HT115,and (C)H23butshowed little effecton
the growth of theWnt-independent cancer cell line (D) H460. Cells from each cell line (23 106 cells/mice) were injected subcutaneously into the flanks of nudemice.
(E) MSAB also inhibited tumor growth of MMTV-Wnt1 transgenic mice. MSAB (10 or 20 mg/kg) was administered at the point when the tumor volume reached
40 mm3 and was injected intraperitoneally once per day for 2 weeks. The control group was treated with an equal volume of vehicle. Tumor volumes were
measured with a caliper every 2 days. The numbers of mice examined are as follows: HCT116 (DMSO control: n = 11; 10 mg/kg MSAB treated: n = 8; 20 mg/kg
MSAB treated: n = 7), HT115 (DMSO control: n = 8; MSAB treated: n = 10), H23 (DMSO control: n = 7; MSAB treated: n = 7), H460 (DMSO control: n = 7; MSAB
treated: n = 7), and MMTV-Wnt1 (DMSO control: n = 7; CTM treated: n = 7).
See also Figure S2 and Table S1.using cell lines, MSAB is capable of inhibiting Wnt-dependent
tumor growth in vivo.
MSAB Inhibits b-Catenin Activity and Induces
Proteasome-Dependent Degradation of b-Catenin
To further understand the inhibitory effects of MSAB on Wnt/
b-catenin pathway, we first assessed the effects of MSAB treat-ment on the expression of Wnt/b-catenin downstream target
genes. Expression level of Wnt/b-catenin downstream pathway
genes, including AXIN-2, c-MYC, Cyclin D1, and BMP4, was
examined in HCT116 cells at the mRNA or protein level, which
decreased in response to MSAB treatment in a dose-dependent
manner (Figure 3A). Similar observations were made for DLD-1,
SW480, and LS174T cells, showing decreased level of proteinsCell Reports 16, 28–36, June 28, 2016 31
Figure 3. MSAB Inhibits b-Catenin Activity and Stimulates Proteasomal Degradation of b-Catenin
(A) MSAB decreasesmRNA and protein levels of endogenousWnt target genes in HCT116 cells. Cells were treated with MSAB for 20 hr, andmRNA levels of Wnt
target genes were measured by qRT-PCR. Data shown represent the mean of three independent qRT-PCR reactions, graphed as relative expression level
compared to that of DMSO-treated control. The effects ofMSAB onWnt target gene products in HCT116 cells were examined through western blot analyses. The
level of b-actin was used as a loading control.
(B) Chromatin immunoprecipitation (ChIP) PCR results demonstrate that the occupancy level of b-catenin inWnt target gene promoters decreased in response to
MSAB treatment. HCT116 cells were treated with DMSO orMSAB (5 or 10 mM), followed by ChIP using immunoglobulin G (IgG; negative control) or anti-b-catenin
antibody. Fold-enrichment over IgG control of DMSO treated sample is shown for promoter regions of Axin2, c-Myc, and Cyclin D1.
(C) MSAB decreasesWnt-mediated nuclear accumulation of b-catenin levels. HCT116 cells were treated with MSAB for 12, 15, or 18 hr, and fractionated lysates
were analyzed by western blotting for active b-catenin. Lamin B and tubulin serve as loading controls.
(D) MSAB treatment downregulates the level of active b-catenin. HCT116 and SW480 cells were treated with DMSO or MSAB, and whole-cell lysates were
subjected to western blot analysis.
(E) MSAB induces degradation of b-catenin in a proteasome-dependent manner. Left: HA-tagged ubiquitin was transiently overexpressed in HCT116 or SW480
cells, which were treated with 5 mM MSAB for 16 hr, followed by addition of DMSO or 10 mM MG132 for 4 hr. b-Catenin was immunoprecipitated using anti-
b-catenin antibody. Input and immunoprecipitated fractions were analyzed bywestern blot analysis to examine the protein level of HA-Ub, b-catenin, and b-actin.
Right: HCT116 cells were treated with 5 mMMSAB for 16 hr, followed by the addition of DMSO or 10 mMMG132 for 4 hr. b-Catenin was immunoprecipitated using
anti-b-catenin antibody. Input and immunoprecipitated fractions were analyzed by western blot analysis to detect endogenous ubiquitin and b-catenin.
See also Figure S3.encoded by target genes c-MYC and Cyclin D1 in response to
MSAB (Figure S3A). Next, in order to determine if MSAB disrupts
the recruitment of b-catenin to the promoter region of its target
genes, we carried out chromatin immunoprecipitation assays.
The occupancy level of b-catenin in these promoter regions
was significantly decreased by MSAB treatment (Figure 3B).
To determine if this could be due to decreased levels of nuclear
b-catenin, we examined the effects of MSAB on nuclear translo-
cation of b-catenin. Cytoplasmic and nuclear fractions were ex-
tracted fromHCT116 cells treated withMSAB over a time course
and fractions were examined by western blot analysis. MSAB
treatment resulted in a reduction in the level of ABC in the nuclear32 Cell Reports 16, 28–36, June 28, 2016fraction, accompanied by an increase in ABC in cytoplasmic
fractions (Figure 3C). However, the increase in cytoplasmic
ABC did not appear sufficient to account for the magnitude of
loss of nuclear ABC, leading to the hypothesis that MSAB down-
regulates the overall level of b-catenin. In order to test this
possibility, we examined the effect of MSAB on ABC levels
in whole-cell lysates and found that the total level of ABC
decreased while the abundance of phospho-b-catenin (p-b-cat-
enin) increased in response to MSAB treatment in HCT116 and
SW480 cells (Figure 3D). Similar observations were made in
DLD-1 and LS174T cells, where ABC levels decreased in
response to MSAB (Figure S3A). These results prompted the
idea that MSAB might facilitate increased ubiquitination and
proteasomal degradation of b-catenin. To test this possibility,
HCT116 and SW480 cells expressing hemagglutinin-tagged
ubiquitin (HA-Ub) were treated with MSAB, followed by protea-
some inhibitor MG132 (Figure 3E). Based on western blot
analysis of whole-cell lysate (Figure 3E, top), we found that
MSAB-induced downregulation of b-catenin was markedly
suppressed by proteasome inhibition. Furthermore, western
blot analysis of immunoprecipitated b-catenin (Figure 3E, bot-
tom) revealed that ubiquitination of b-catenin was significantly
increased upon MSAB treatment, which became more evident
when MG132 was treated in combination. Similar results were
obtained when probing for endogenous ubiquitin (Figure 3E,
right panels). Next, we tested whether MSAB affects b-catenin
associated with E-cadherin. Results of the co-immunoprecipita-
tion assay demonstrated that the level of b-catenin interacting
with E-cadherin remained unaffected after MSAB treatment
(Figure S3B). Together, these results demonstrate that MSAB in-
creases ubiquitination and proteasome-dependent degradation
of b-catenin, which leads to its inhibitory effect onWnt/b-catenin
signaling pathway.
MSAB Targets the b-Catenin Molecule
In order to understand structural elements of MSAB that are crit-
ically involved in b-catenin inhibition, we conducted a structure-
activity relationship study using 82 structural analogs that were
synthesized or purchased. Because MSAB was identified as
an inhibitor of the Wnt/b-catenin signaling pathway through a
TOP-Luc activity assay in HCT116 cells, these analogs were
tested by the same assay and the inhibitory concentration
50% (IC50) of each compound was calculated. Representative
analogs are shown in Table S2. Structure-activity relationship
study of phenylsulfonamidobenzoates provided information on
the critical residues responsible for the inhibitory activity toward
the Wnt/b-catenin signaling pathway. The para-substitution of
phenyl ring is important for maintaining the activity, and fluoro-
or chloro- substitutions result in loss of its inhibitory activity. Phe-
nylsulfonamidobenzamides with amides in place of ester groups
resulted in complete loss of activity (Figure 4A). The methoxy-
phenyl methylbenzoate analog, compound 9A (Figure 4B), was
the most potent in the TOP-Luc reporter assay (Table S2).
Hence, we tested whether 9A shows similar effects as MSAB,
and we found that it can suppress the increase in active b-cate-
nin levels in HEK293T cells induced by Wnt3a-CM treatment
(Figure 4C), and reduce the expression level of Wnt/b-catenin
target genes AXIN-2, c-MYC, and Cyclin D1 in DLD-1 cells (Fig-
ure S4A). Analyses on cell viability of Wnt/b-catenin-dependent
HCT116 cells and -independent A673 and H460 cancer cells
demonstrated that 9A is also capable of inhibiting proliferation
of HCT116 cells, while showing little effect on the viability of
A673 and H460 cells (Figure S4B). These results demonstrate
that compound 9A, a structural analog of MSAB, is also a potent
and selective inhibitor of the Wnt/b-catenin signaling pathway
and underline the potential of MSAB as a lead compound for
Wnt/b-catenin inhibitor development.
To identify the direct target(s) of MSAB, we used a pull-down
approach using biotinylated MSAB analogs. Based on the re-
sults of the structure-activity relationship study, a biotin moietyconnected to a linker was attached to MSAB (Biotin-MSAB), as
well as to a negative control, a structural analog of MSAB that
lacks the inhibitory effect on TOP-Luc (Biotin-nc-MSAB) (Fig-
ure 4D, top and middle). A TOP-Luc assay was carried out to
check whether MSAB remains active following biotinylation,
and as anticipated, TOP-Luc activity was inhibited by Biotin-
MSAB, whereas, Biotin-nc-MSAB did not show any inhibitory
effect (Figure S4C). We also checked the effects of Biotin-
MSAB and Biotin-nc-MSAB on ABC level in HEK293T cell
lines. Biotin-MSAB significantly suppressed the increase in
ABC induced by Wnt3a-CM in a dose-dependent manner (Fig-
ure S4D). Based on these results, we moved ahead and carried
out pull-down assays using Biotin-MSAB and Biotin-nc-MSAB
to identify binding targets ofMSAB. Proteins that co-precipitated
with Biotin-MSAB or Biotin-nc-MSAB were identified through
tandem mass spectrometry (Table S3). Proteins detected with
at least two unique peptides were selected for comparison,
and interestingly, b-catenin ranked among the top candidates
that showed a stronger association with Biotin-MSAB than
with Biotin-nc-MSAB. The specific enrichment of b-catenin in
the Biotin-MSAB fraction was confirmed by western blot anal-
ysis (Figure 4D, bottom).
In order to check whether MSAB binds b-catenin, NMR anal-
ysis was first carried out. Adding purified recombinant b-catenin
protein to MSAB shifted the 1H peaks of MSAB, demonstrating
an interaction between the two (Figure 4E). In addition, we con-
ducted SPR spectroscopy to test whether compound 9A, an
MSAB analog with comparable efficiency of inhibiting Wnt
signaling activity to MSAB, can also bind b-catenin. Purified
recombinant His-b-catenin proteins were captured on a CM5
chip, and then various concentrations of 9A were allowed to
flowover, and as a result, 9A also showed dose-dependent bind-
ing to b-catenin (Figure 4F). Furthermore, in order to identify the
domain of b-catenin that interacts with MSAB, in vitro pull-down
assays were carried out using purified recombinant proteins of
truncated forms of b-catenin. As a result, the Armadillo repeat
region (amino acid residues 136–686), as opposed to N-terminal
(residues 1–137) or C-terminal (residues 666–781) fragments of
b-catenin, showed direct binding with immobilized Biotin-
MSAB (Figure 4G). In order to validate the binding of MSAB to
the Armadillo repeat region of b-catenin, we carried out NMR as-
says with MSAB and full-length or truncated forms of b-catenin.
As a result, Armadillo repeat region 2 (residues 301-670) showed
an interaction with MSAB, in contrast to the Armadillo repeat
region 1 (residues 142–305), N-terminal fragment, or C-terminal
fragment (Figure S4E). These observations suggest that MSAB
binds to b-catenin, most likely via its Armadillo repeat region.
Altogether, our results corroborate the potential of MSAB as a
lead compound for developing therapeutics that can specifically
target Wnt/b-catenin dependent cancer cells.
DISCUSSION
Aberrant Wnt signaling is directly linked to multiple types of can-
cers, including colon cancer, sarcoma, melanoma, and hepato-
cellular carcinoma (Bafico et al., 2004; Clevers and Nusse, 2012;
Rubinfeld et al., 1997; Vijayakumar et al., 2011). Previous reports
have shown the crucial role of b-catenin in Wnt-dependentCell Reports 16, 28–36, June 28, 2016 33
Figure 4. MSAB Binds to b-Catenin
(A) Summary of SAR (structure-activity relationship) for phenylsulfonamidobenzoates as inhibitors of the Wnt/b-catenin signaling pathway.
(B) Chemical structure of methyl 3-{[(4-methoxyphenyl)sulfonyl]amino} benzoate (9A).
(C) Active b-catenin level increased by Wnt3a-CM is suppressed by 9A treatment in HEK293T cells. The results of western blot analysis probing for active
b-catenin are shown, where b-actin serves as a loading control.
(D) The chemical structure of biotinylated MSAB (Biotin-MSAB, top) or biotinylated negative control MSAB (Biotin-nc-MSAB, middle). Bottom: b-catenin as-
sociates with Biotin-MSAB. Cell lysate was incubated with Biotin-MSAB or Biotin-nc-MSAB, followed by streptavidin pull-down assay. The level of b-catenin
associated with Biotin-MSAB or Biotin-nc-MSAB was analyzed through western blot analysis.
(E) Identification of MSAB binding to b-catenin using 1D 1H NMR spectroscopy. Assessment of binding is based on the following experiments: blue, normal 1H
spectrum of MSAB in the absence of protein (1D); red, normal 1H spectrum of MSAB and b-catenin protein (1D); green, 1H spectrum of MSAB and b-catenin
protein saturation transfer difference (STD).
(F) Physical interaction between compound 9A, anMSAB analog, and b-catenin was tested using SPR. Various concentrations of MSAB ranging from 0 to 125 mM
in 2-fold dilution series were tested in duplicate. The binding signal from a reference flow cell containing no protein was subtracted to account for detection of
specific interaction between the compound and b-catenin. Compound 9A physically interacted with b-catenin in a concentration-dependent manner.
(G) MSAB binds to the Armadillo repeat region of b-catenin. In vitro pull-down assays were carried out using Streptavidin beads, Biotin-MSAB, and histidine-
tagged recombinant proteins of different regions of b-catenin: full-length (amino acid residues: 1–781), N terminal (1–137), Armadillo repeat (136–686), or
C terminal (666–781). Input and pull-down fractions were examined through western blot analysis using anti-His antibody.
See also Figure S4 and Tables S2 and S3.cancer cells and demonstrated that downregulation of b-catenin
can suppress tumorigenesis (Kwong et al., 2002; Rosenbluh
et al., 2012). Although the discovery of several previously re-
ported Wnt/b-catenin pathway inhibitors (Anastas and Moon,
2013; Kahn, 2014) have advanced our knowledge on Wnt/b-cat-
enin signaling, there is still a need for discovering novel inhibitors
that can selectively suppress hyperactive b-catenin. In the cur-
rent study, we have identified a class of small molecules that
can specifically inhibit the Wnt/b-catenin signaling pathway in34 Cell Reports 16, 28–36, June 28, 2016multiple Wnt/b-catenin-dependent cancer cells while showing
minimal anti-proliferative effects on Wnt-independent cells,
in vitro as well as in vivo. The effect of MSAB on the level of acti-
vated b-catenin in Wnt3a-stimulated HEK293T cells shows that
MSAB is capable of targeting wild-type b-catenin when its level
is elevated. Additionally, MSAB appears to target the oncogenic
b-catenin mutant as well, based on the observation that MSAB
inhibited the proliferation of cells such as LS174T, which harbor
only the mutant form of b-catenin (Chan et al., 2002; Korinek
et al., 1997). The observation that MSAB causes degradation of
this oncogenic mutant isoform of b-catenin is noteworthy, since
this type of mutant b-catenins lack residues required for surveil-
lance and degradation by the destruction complex. The func-
tional consequence is that these mutants cannot be efficiently
dealt with by approaches that target upstream members of
the signaling pathway by activating the destruction complex.
Altogether, these results clearly demonstrate the therapeutic
potential of MSAB and its functional derivatives for targeting
b-catenin-mediated cancers.
SAR analysis results not only corroborated the effectiveness of
MSABasa lead compoundbut alsoprovideduswith tools to carry
out a search for proteins that interact with MSAB in cell extracts
through affinity purification followed by tandem mass spectrom-
etry.Wewerehoping to find clues aboutMSAB-interacting factors
that would affect protein stability or nuclear translocation of b-cat-
enin. However, rather unexpectedly, one of the top hits turned out
to be b-catenin itself. The results of our NMR and SPR assays
demonstrating binding between b-catenin and MSAB or an
MSAB analog 9A in vitro further strengthen the possibility that
MSAB directly affects b-catenin function, presumably by inducing
allosteric conformational changes or affecting interactions be-
tween b-catenin and its regulators. Nevertheless, the precise
mechanistic details of MSAB’s action remain unclear and will
require further investigation of b-catenin-interacting proteins,
which are affected by MSAB, or an in-depth characterization of
how b-catenin is directly affected by MSAB. Such information on
active b-catenin regulation is likely to provide additional perspec-
tives on therapeutic strategies against Wnt/b-catenin-dependent
cancer, as well as novel insights into Wnt/b-catenin biology.
EXPERIMENTAL PROCEDURES
Chemical Screen
High-throughput chemical screening was performed as previously described
(Raj et al., 2011; Stanton et al., 2009), with some modifications. To screen
inhibitors targeting the Wnt/b-catenin signaling pathway, HCT116-TOP cells
(HCT116 cells stably transfected with TOPFLASH [TCF/LEF1-optimized pro-
moter]-firefly luciferase reporter) were seeded using an automated plate filler
in 384-well plates and incubated at 37C overnight. The next day, each
small-molecule compound (compound library from Chembridge and Broad
Institute) was pin-transferred to each plate. Plates were covered with lids
and incubated at 37C for 20 hr. The following day, assay plates were allowed
to equilibrate to room temperature for 10 min. Luciferase assay reagent
(Steady-Glo Luciferase Assay System, Promega) was added to each well,
incubated for 15 min, and then read using a PerkinElmer Envision luminometer
to quantitate luciferase levels. Compounds that decrease luciferase activity
were selected as hits. Luciferase values were normalized to the positive and
negative controls to determine a normalized percent inhibition. Based on the
normalized luciferase values, compounds showing >50% inhibition in both
replicates compared to DMSO control were considered as active compounds.
All small molecules were tested in duplicate.
Animal Experiments
All animal experiments were reviewed and approved by the Massachusetts
General Hospital Subcommittee on Research Animal Care.
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